Hepatitis B virus-induced hepatocarcinogenesis: A virological and oncological perspective.
HBV-DNA
cancer
hepatitis B virus
hepatocellular carcinoma
hepatocyte
tenofovir
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
24
04
2021
received:
03
02
2021
accepted:
03
05
2021
pubmed:
19
5
2021
medline:
5
10
2021
entrez:
18
5
2021
Statut:
ppublish
Résumé
Hepatitis B virus (HBV) is a partially double-stranded DNA virus associated with hepatocellular carcinoma (HCC). The viral integration into the hepatocyte genome, the viral protein-induced oncogenesis, the increased hepatocyte turnover and the chronic inflammatory response towards HBV are all hypothesized mechanisms for the development of HCC. The fact that HBV infection and HCC prevalence show different correlations in various regions of the world indicates that there may be virus-independent phenomena for cancer development in these regions. From this point of view, it is important to review our knowledge and to examine the relationship between HBV and HCC in the light of current data. In this article, we investigate the relationship between HBV and HCC by presenting epidemiological and microbiological data, accompanied by the principles of viral oncogenesis.
Substances chimiques
DNA, Viral
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1104-1109Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Carman WF, Thomas HC. Genetic variation in hepatitis B virus. Gastroenterology. 1992;102(2):711-719.
Zapatka M, Borozan I, Brewer DS, et al. The landscape of viral associations in human cancers. Nat Genet. 2020;52(3):320-330.
Cantalupo PG, Katz JP, Pipas JM. Viral sequences in human cancer. Virology. 2018;513:208-216.
Wang F-S, Fan J-G, Zhang Z, Gao B, Wang H-Y. The global burden of liver disease: the major impact of China. Hepatol Baltim Md. 2014;60(6):2099-2108.
El-Serag HB, et al. Epidemiology of Hepatocellular Carcinoma. In: Arias IM, Alter HJ, Boyer JL, eds. The Liver, 1st edn. Wiley; 2020:758-772.
Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet Lond Engl. 1981;2(8256):1129-1133.
Evans AA, Chen G, Ross EA, Shen F-M, Lin W-Y, London WT. Eight-year follow-up of the 90,000-person Haimen City cohort:i Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2002;11(4):369-376.
Chen T, Qian G, Fan C, et al. Qidong hepatitis B virus infection cohort: a 25-year prospective study in high risk area of primary liver cancer. Hepatoma Res. 2018;4:4.
Zhou R, Liu M, Liang X, Su M, Li R. Clinical features of aflatoxin B1-exposed patients with liver cancer and the molecular mechanism of aflatoxin B1 on liver cancer cells. Environ Toxicol Pharmacol. 2019;71:103225.
Di Bisceglie AM, Lyra AC, Schwartz M, et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol. 2003;98(9):2060-2063.
Su F-H, Le TN, Muo C-H, Te SA, Sung F-C, Yeh C-C. Chronic hepatitis B virus infection associated with increased colorectal cancer risk in Taiwanese population. Viruses. 2020;12(1):97.
Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152(4):745-761.
Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450-1462.
Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012;21(3):283-296.
Takeda H, Takai A, Kumagai K, et al. Multiregional whole-genome sequencing of hepatocellular carcinoma with nodule-in-nodule appearance reveals stepwise cancer evolution. J Pathol. 2020;252(4):398-410.
Decorsière A, Mueller H, van Breugel PC, et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature. 2016;531(7594):386-389.
Kang T-W, Yevsa T, Woller N, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 2011;479(7374):547-551.
Chang O, Yano Y, Masuzawa A, Fukushima N, Teramura K, Hayashi Y. The cytological characteristics of small cell change of dysplasia in small hepatic nodules. Oncol Rep. 2010;23(5):1229-1232.
Slagle BL, Bouchard MJ. Role of HBx in hepatitis B virus persistence and its therapeutic implications. Curr Opin Virol. 2018;30:32-38.
Liang TJ. Virology: the X-Files of hepatitis B. Nature. 2016;531(7594):313-314.
Gao Q, Zhu H, Dong L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell. 2019;179(5):1240.
Sung W-K, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012;44(7):765-769.
Rebouissou S, Nault J-C. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol. 2020;72(2):215-229.
Yang YM, Kim SY, Seki E. Inflammation and liver cancer: molecular mechanisms and therapeutic targets. Semin Liver Dis. 2019;39(1):26-42.
Sunami Y, Ringelhan M, Kokai E, et al. Canonical NF-κB signaling in hepatocytes acts as a tumor-suppressor in hepatitis B virus surface antigen-driven hepatocellular carcinoma by controlling the unfolded protein response. Hepatol Baltim Md. 2016;63(5):1592-1607.
Xiang X, Qin H-G, You X-M, et al. Expression of P62 in hepatocellular carcinoma involving hepatitis B virus infection and aflatoxin B1 exposure. Cancer Med. 2017;6(10):2357-2369.
Qi L-N, Li L-Q, Chen Y-Y, et al. Genome-wide and differential proteomic analysis of hepatitis B virus and aflatoxin B1 related hepatocellular carcinoma in Guangxi, China. PLoS One. 2013;8(12):e83465.
Haybaeck J, Zeller N, Wolf MJ, et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell. 2009;16(4):295-308.
Balakrishnan L, Milavetz B. Epigenetic regulation of viral biological processes. Viruses. 2017;9(11):346.
Franci G, Ciotta A, Altucci L. The Jumonji family: past, present and future of histone demethylases in cancer. Biomol Concepts. 2014;5(3):209-224.
Franci G, Miceli M, Altucci L. Targeting epigenetic networks with polypharmacology: a new avenue to tackle cancer. Epigenomics. 2010;2(6):731-742.
Tsai K, Cullen BR. Epigenetic and epitranscriptomic regulation of viral replication. Nat Rev Microbiol. 2020;18(10):559-570.
Lee J, Tsai K-N, Ou J-HJ. Mechanisms of Hepatitis B Virus-Induced Hepatocarcinogenesis. Recent Results Cancer Res Fortschritte Krebsforsch Progres Dans Rech Sur Cancer. 2021;217:47-70.
Fernandez AF, Rosales C, Lopez-Nieva P, et al. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res. 2009;19(3):438-451.
Kuss-Duerkop SK, Westrich JA, Pyeon D. DNA tumor virus regulation of host DNA methylation and its implications for immune evasion and oncogenesis. Viruses. 2018;10(2):82.
Zhang P, Torres K, Liu X, Liu C-G, Pollock RE. An overview of chromatin-regulating proteins in cells. Curr Protein Pept Sci. 2016;17(5):401-410.
Alarcon V, Hernández S, Rubio L, et al. The enzymes LSD1 and Set1A cooperate with the viral protein HBx to establish an active hepatitis B viral chromatin state. Sci Rep. 2016;6:25901.
Morishita A, Fujita K, Iwama H, et al. Role of microRNA-210-3p in hepatitis B virus-related hepatocellular carcinoma. Am J Physiol Gastrointest Liver Physiol. 2020;318(3):G401-G409.
Li X, Yuan M, Song L, Wang Y. Silencing of microRNA-210 inhibits the progression of liver cancer and hepatitis B virus-associated liver cancer via targeting EGR3. BMC Med Genet. 2020;21(1):48.
Park YM, Jang JW, Yoo SH, et al. Combinations of eight key mutations in the X/preC region and genomic activity of hepatitis B virus are associated with hepatocellular carcinoma. J Viral Hepat. 2014;21(3):171-177.
Suzuki Y, Maekawa S, Komatsu N, et al. Hepatitis B virus (HBV)-infected patients with low hepatitis B surface antigen and high hepatitis B core-related antigen titers have a high risk of HBV-related hepatocellular carcinoma. Hepatol Res Off J Jpn Soc Hepatol. 2019;49(1):51-63.
Halgand B, Desterke C, Rivière L, et al. Hepatitis B virus pregenomic RNA in hepatocellular carcinoma: a nosological and prognostic determinant. Hepatology. 2018;67(1):86-96.
Chen C-J, Yang H-I, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65-73.
Kim G-A, Lim Y-S, Han S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018;67(5):945-952.
Lee HA, Lee HW, Kim IH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther. 2020;52(1):196-204.
Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int. 2016;36(9):1239-1251.
Liaw Y-F, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521-1531.
Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut. 2011;60(8):1109-1116.
Flemming JA, Terrault NA. Tenofovir vs entecavir for hepatocellular carcinoma prevention in patients with chronic hepatitis B: one of these things is not like the other. JAMA Oncol. 2019;5(1):17-18.
Choi W-M, Choi J, Lim Y-S. Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2020;19(2):246-258
Arslan F, Vahaboglu H. Tenofovir for the prevention of HCC in patients with cirrhosis. Am J Gastroenterol. 2020;115(2):302.
Péneau C, Imbeaud S, La Bella T, et al. Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. Gut. 2021;1-11.
Liang YJ, Teng W, Chen CL, et al. Clinical implications on HBV preS/S mutations and the effects of preS2 deletion on mitochondria, liver fibrosis, and cancer development. Hepatology. https://doi.org/10.1002/hep.31789 [Epub ahead of print]
Campbell C, Wang T, McNaughton AL, Barnes E, Matthews PC. Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. J Viral Hepat. 2021;28(3):493-507.